NPI: 1053363119 · ANCHORAGE, AK 99508 · General Acute Care Hospital · NPI assigned 05/17/2006
Authorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
| Authorized Official | ANDERSON, DONALD (ASSISTANT SECRETARY OF ENROLLMENTS) |
| NPI Enumeration Date | 05/17/2006 |
Other providers sharing the same authorized official: ANDERSON, DONALD
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 420,444 | $23.87M |
| 2019 | 396,285 | $24.63M |
| 2020 | 298,876 | $19.32M |
| 2021 | 302,400 | $21.95M |
| 2022 | 306,729 | $24.73M |
| 2023 | 304,072 | $25.24M |
| 2024 | 267,667 | $21.73M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 46,022 | 39,502 | $30.97M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 56,881 | 49,082 | $22.32M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 68,480 | 60,469 | $16.42M |
| G0378 | Hospital observation service, per hour | 13,044 | 8,467 | $9.97M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7,396 | 6,817 | $5.99M |
| 41899 | Unlisted procedure, dentoalveolar structures | 2,217 | 2,087 | $5.03M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 44,491 | 37,871 | $3.14M |
| 70450 | Computed tomography, head or brain; without contrast material | 8,043 | 7,360 | $3.00M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 34,449 | 28,150 | $2.61M |
| 71045 | Radiologic examination, chest; single view | 28,781 | 25,166 | $2.42M |
| 96375 | Therapeutic injection; each additional sequential IV push | 26,497 | 20,126 | $2.39M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2,848 | 2,650 | $1.93M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 15,561 | 11,198 | $1.81M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3,328 | 3,195 | $1.56M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 38,232 | 8,237 | $1.56M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2,225 | 2,093 | $1.50M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 10,598 | 9,848 | $1.36M |
| 96361 | Intravenous infusion, hydration; each additional hour | 26,993 | 21,418 | $1.35M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 12,356 | 11,523 | $1.32M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 23,407 | 8,291 | $1.30M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1,210 | 1,106 | $1.29M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 19,788 | 14,733 | $1.24M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 7,736 | 7,124 | $1.19M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 8,884 | 7,823 | $1.05M |
| 71046 | Radiologic examination, chest; 2 views | 9,783 | 9,056 | $1.01M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2,545 | 2,380 | $991K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 11,115 | 3,819 | $928K |
| 80053 | Comprehensive metabolic panel | 105,997 | 87,524 | $848K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 4,407 | 2,979 | $798K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1,983 | 1,841 | $779K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 7,935 | 6,323 | $752K |
| J3490 | Unclassified drugs | 28,324 | 11,952 | $716K |
| 70496 | 1,484 | 1,390 | $710K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 115,033 | 93,306 | $669K |
| 96376 | 8,189 | 6,052 | $659K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 263 | 242 | $654K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 13,029 | 11,289 | $651K |
| 97597 | 7,556 | 3,650 | $650K | |
| 70498 | 1,510 | 1,418 | $634K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 1,315 | 1,204 | $631K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 16,752 | 4,083 | $590K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 70,969 | 26,008 | $572K |
| J7030 | Infusion, normal saline solution , 1000 cc | 12,389 | 9,929 | $542K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 16,210 | 13,074 | $537K |
| 88307 | 1,368 | 1,176 | $452K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 3,131 | 2,921 | $401K |
| 36430 | 1,990 | 1,230 | $400K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 991 | 940 | $395K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 6,258 | 5,377 | $385K |
| C1769 | Guide wire | 5,525 | 4,667 | $373K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1,417 | 1,312 | $354K |
| 84443 | Thyroid stimulating hormone (TSH) | 24,937 | 23,356 | $348K |
| 93971 | 1,781 | 1,645 | $339K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 15,764 | 10,329 | $338K |
| 36902 | 1,199 | 1,087 | $324K | |
| 29581 | 4,276 | 1,467 | $321K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 427 | 392 | $318K |
| 36591 | 4,838 | 2,538 | $293K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 5,763 | 4,012 | $292K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 554 | 525 | $275K |
| 99153 | Mod sedat endo service >5yrs | 3,033 | 2,712 | $273K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 8,137 | 7,625 | $272K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 8,188 | 7,627 | $270K |
| 73610 | 2,163 | 1,982 | $259K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 12,807 | 9,302 | $258K |
| 88342 | 2,494 | 2,289 | $254K | |
| 97116 | 8,729 | 3,179 | $251K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3,106 | 2,972 | $250K |
| 76801 | 1,092 | 1,006 | $237K | |
| 73562 | 1,982 | 1,835 | $219K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 23,396 | 19,662 | $218K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 8,736 | 8,253 | $217K |
| 73030 | 2,277 | 2,021 | $217K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 2,630 | 2,127 | $216K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 17,811 | 15,960 | $216K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 30,861 | 23,647 | $212K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 6,079 | 2,482 | $210K |
| J9271 | Injection, pembrolizumab, 1 mg | 19 | 14 | $208K |
| J7120 | Ringers lactate infusion, up to 1000 cc | 4,454 | 3,553 | $203K |
| 80061 | Lipid panel | 17,025 | 16,264 | $196K |
| 84484 | 27,789 | 20,572 | $192K | |
| 99152 | 3,756 | 3,369 | $192K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 5,666 | 4,665 | $183K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2,696 | 2,060 | $179K |
| 70486 | 603 | 557 | $173K | |
| 74018 | 1,846 | 1,595 | $172K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 1,926 | 1,547 | $172K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 1,166 | 1,077 | $172K |
| 73130 | 1,727 | 1,532 | $171K | |
| J7050 | Infusion, normal saline solution, 250 cc | 7,391 | 3,886 | $165K |
| 83880 | 7,949 | 7,061 | $163K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | 821 | 613 | $159K |
| 97535 | Self-care/home management training, each 15 minutes | 4,594 | 2,186 | $158K |
| 73630 | 1,575 | 1,421 | $156K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | 503 | 481 | $155K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4,190 | 3,847 | $153K |
| 96415 | 1,442 | 1,194 | $150K | |
| J2704 | Injection, propofol, 10 mg | 13,609 | 11,823 | $146K |
| H0007 | Alcohol and/or drug services; crisis intervention (outpatient) | 4,204 | 468 | $144K |
| 83036 | Hemoglobin; glycosylated (A1C) | 17,382 | 16,624 | $142K |
| 76830 | Ultrasound, transvaginal | 1,101 | 1,010 | $141K |
| D7140 | Extraction, erupted tooth or exposed root | 411 | 392 | $135K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 18,623 | 14,529 | $134K |
| D0150 | Comprehensive oral evaluation - new or established patient | 443 | 418 | $130K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 6,110 | 5,780 | $129K |
| 80048 | Basic metabolic panel (calcium, ionized) | 22,561 | 18,841 | $127K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 8,416 | 540 | $124K |
| 0240U | 1,177 | 1,130 | $123K | |
| 10061 | 720 | 678 | $123K | |
| C1766 | Introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away | 347 | 317 | $123K |
| D1120 | Prophylaxis - child | 403 | 384 | $122K |
| 72100 | 1,242 | 1,168 | $122K | |
| 83690 | 22,906 | 19,833 | $118K | |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1,402 | 1,158 | $116K |
| C1732 | Catheter, electrophysiology, diagnostic/ablation, 3d or vector mapping | 54 | 50 | $115K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 14,212 | 12,576 | $112K |
| 81001 | 44,091 | 39,084 | $112K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 471 | 281 | $108K |
| 12001 | 1,047 | 1,002 | $107K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 86 | 77 | $107K |
| 81025 | 14,863 | 13,387 | $104K | |
| 87510 | 5,429 | 5,011 | $103K | |
| 87480 | 5,429 | 5,011 | $103K | |
| 87660 | 5,429 | 5,011 | $103K | |
| 86480 | 1,968 | 1,883 | $101K | |
| 97162 | 2,374 | 2,222 | $97K | |
| 86920 | 1,660 | 1,272 | $95K | |
| 90715 | 2,728 | 2,579 | $94K | |
| 87040 | 12,294 | 6,405 | $93K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 13,894 | 12,736 | $91K |
| 84702 | 6,647 | 5,535 | $90K | |
| 85027 | 19,082 | 16,105 | $90K | |
| 87150 | 2,959 | 2,616 | $90K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 16,990 | 13,077 | $89K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | 2,993 | 184 | $89K |
| 97129 | 1,096 | 339 | $87K | |
| 77336 | 830 | 366 | $87K | |
| 73590 | 783 | 685 | $86K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 9,194 | 7,262 | $81K |
| 96367 | 2,936 | 2,024 | $80K | |
| 86141 | 7,618 | 6,628 | $80K | |
| 83970 | 2,516 | 2,271 | $78K | |
| 73110 | 956 | 886 | $77K | |
| 93458 | 25 | 25 | $76K | |
| 84439 | 9,836 | 9,198 | $76K | |
| 73502 | 1,059 | 966 | $75K | |
| 87077 | 11,029 | 8,102 | $74K | |
| 97161 | 1,762 | 1,654 | $74K | |
| J1170 | Injection, hydromorphone, up to 4 mg | 7,814 | 5,495 | $74K |
| 88341 | 507 | 426 | $73K | |
| 88304 | 1,606 | 1,485 | $72K | |
| 82728 | 6,360 | 5,931 | $72K | |
| 83605 | 9,558 | 7,114 | $69K | |
| 80074 | 1,824 | 1,719 | $68K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 10,099 | 8,872 | $68K |
| D1206 | Topical application of fluoride varnish | 236 | 222 | $67K |
| D0220 | Intraoral - periapical first radiographic image | 270 | 260 | $66K |
| 90791 | Psychiatric diagnostic evaluation | 811 | 579 | $65K |
| D0230 | Intraoral - periapical each additional radiographic image | 263 | 254 | $64K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 471 | 380 | $64K |
| 86780 | 5,629 | 5,305 | $64K | |
| J2060 | Injection, lorazepam, 2 mg | 6,620 | 4,971 | $63K |
| D1351 | Sealant - per tooth | 212 | 203 | $63K |
| 86803 | 4,984 | 4,722 | $63K | |
| 82077 | 5,077 | 4,288 | $61K | |
| 83735 | 13,047 | 9,912 | $61K | |
| 59025 | Fetal non-stress test | 649 | 403 | $59K |
| 94726 | 833 | 780 | $59K | |
| 84466 | 5,317 | 5,037 | $56K | |
| 36415 | Collection of venous blood by venipuncture | 117,264 | 95,717 | $55K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 113 | 106 | $52K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1,716 | 1,634 | $52K |
| 82607 | 4,325 | 4,107 | $51K | |
| 12011 | 523 | 490 | $51K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 7,231 | 4,837 | $51K |
| J1756 | Injection, iron sucrose, 1 mg | 1,017 | 428 | $51K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 6,326 | 5,026 | $51K |
| 73560 | 443 | 412 | $49K | |
| 92526 | 1,000 | 473 | $49K | |
| 82962 | 27,926 | 13,149 | $48K | |
| 82803 | 3,290 | 2,755 | $48K | |
| 88108 | 785 | 649 | $48K | |
| 87070 | 6,850 | 6,086 | $48K | |
| J1644 | Injection, heparin sodium, per 1000 units | 9,918 | 5,508 | $47K |
| 87186 | 5,538 | 5,130 | $46K | |
| 10060 | 410 | 395 | $46K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 289 | 279 | $45K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 289 | 276 | $45K |
| 97130 | 859 | 265 | $45K | |
| D0240 | 191 | 186 | $45K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1,446 | 347 | $45K |
| 94729 | 951 | 893 | $44K | |
| J0690 | Injection, cefazolin sodium, 500 mg | 8,064 | 6,166 | $43K |
| D0272 | Bitewings - two radiographic images | 179 | 171 | $43K |
| 86850 | 6,664 | 5,675 | $42K | |
| 93613 | 26 | 24 | $40K | |
| 94060 | 457 | 426 | $40K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 1,354 | 1,102 | $39K |
| 85610 | 15,069 | 13,162 | $39K | |
| 76818 | 200 | 134 | $39K | |
| J1815 | Injection, insulin, per 5 units | 2,421 | 1,326 | $38K |
| A9150 | Non-prescription drugs | 38,498 | 20,975 | $38K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 4,644 | 3,653 | $38K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1,515 | 1,458 | $37K |
| 82570 | 8,292 | 7,440 | $37K | |
| 73140 | 493 | 463 | $36K | |
| 36907 | 90 | 77 | $36K | |
| 77334 | 65 | 52 | $36K | |
| 92523 | 432 | 394 | $35K | |
| A6196 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing | 2,548 | 1,352 | $35K |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | 1,258 | 935 | $35K |
| 96409 | 255 | 140 | $34K | |
| 73090 | 306 | 267 | $34K | |
| D2330 | 116 | 107 | $34K | |
| 80069 | 5,623 | 4,205 | $34K | |
| 85379 | 4,471 | 4,164 | $33K | |
| 93325 | 182 | 167 | $31K | |
| 97166 | 723 | 677 | $31K | |
| 76937 | 537 | 452 | $31K | |
| 84112 | 349 | 320 | $30K | |
| 99215 | Prolong outpt/office vis | 362 | 341 | $30K |
| 83540 | 5,648 | 5,333 | $30K | |
| 12002 | 326 | 305 | $30K | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | 88 | 85 | $29K |
| 93308 | 157 | 138 | $29K | |
| 97542 | 584 | 520 | $29K | |
| 90837 | Psychotherapy, 53 minutes with patient | 657 | 237 | $29K |
| 93798 | 752 | 130 | $28K | |
| 73080 | 274 | 249 | $28K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 262 | 251 | $28K |
| 84703 | 4,432 | 4,088 | $28K | |
| 97163 | 767 | 732 | $28K | |
| 82746 | 2,379 | 2,258 | $28K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1,859 | 1,787 | $28K |
| 84145 | 1,765 | 1,614 | $27K | |
| 86140 | 6,093 | 5,251 | $27K | |
| A9585 | Injection, gadobutrol, 0.1 ml | 1,566 | 1,397 | $27K |
| J3475 | Injection, magnesium sulfate, per 500 mg | 2,376 | 1,650 | $27K |
| 85730 | 6,902 | 6,260 | $27K | |
| 82784 | 2,334 | 2,054 | $26K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 725 | 634 | $26K |
| 87081 | 3,748 | 3,588 | $26K | |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 23 | 12 | $26K |
| 87340 | 3,113 | 2,906 | $25K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | 90 | 86 | $24K |
| 97165 | 502 | 465 | $23K | |
| 82043 | 4,577 | 4,344 | $23K | |
| A6207 | Contact layer, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | 4,042 | 2,022 | $23K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 3,886 | 3,276 | $23K |
| 73620 | 295 | 268 | $23K | |
| 87205 | 6,720 | 5,821 | $23K | |
| 93976 | 100 | 94 | $22K | |
| 96417 | 265 | 195 | $22K | |
| 82075 | 1,145 | 960 | $22K | |
| C1889 | Implantable/insertable device, not otherwise classified | 284 | 228 | $22K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 2,638 | 2,256 | $22K |
| J8540 | Dexamethasone, oral, 0.25 mg | 3,448 | 2,720 | $22K |
| 84403 | 1,046 | 962 | $22K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 562 | 515 | $21K |
| H2021 | Community-based wrap-around services, per 15 minutes | 1,378 | 373 | $21K |
| J0185 | Injection, aprepitant, 1 mg | 77 | 49 | $21K |
| J3480 | Injection, potassium chloride, per 2 meq | 1,114 | 683 | $21K |
| 94010 | 406 | 384 | $21K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 2,498 | 1,722 | $20K |
| 87640 | 792 | 732 | $20K | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 448 | 387 | $20K |
| 87641 | 802 | 740 | $20K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | 75 | 71 | $20K |
| D4355 | 69 | 68 | $20K | |
| 85652 | 8,764 | 7,726 | $20K | |
| 87631 | 199 | 183 | $20K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 624 | 600 | $19K |
| 76770 | 140 | 126 | $19K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 3,574 | 1,096 | $19K |
| 86900 | 8,619 | 6,472 | $19K | |
| 86901 | 8,606 | 6,468 | $19K | |
| 74174 | 27 | 26 | $19K | |
| 87075 | 2,594 | 2,226 | $19K | |
| C9113 | Injection, pantoprazole sodium, per vial | 2,202 | 1,661 | $18K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 39 | 37 | $18K |
| 90832 | Psychotherapy, 30 minutes with patient | 467 | 196 | $18K |
| G0515 | Development of cognitive skills to improve attention, memory, problem solving (includes compensatory training), direct (one-on-one) patient contact, each 15 minutes | 392 | 107 | $18K |
| 80076 | 2,542 | 2,331 | $18K | |
| 84100 | 4,988 | 3,735 | $17K | |
| 83516 | 1,333 | 1,107 | $17K | |
| J1630 | Injection, haloperidol, up to 5 mg | 1,992 | 1,470 | $17K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 2,125 | 1,708 | $17K |
| 80143 | 1,245 | 1,057 | $17K | |
| A4648 | Tissue marker, implantable, any type, each | 135 | 119 | $16K |
| 77295 | 12 | 12 | $16K | |
| J3370 | Injection, vancomycin hcl, 500 mg | 1,861 | 1,205 | $16K |
| C1874 | Stent, coated/covered, with delivery system | 12 | 12 | $16K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 292 | 255 | $16K |
| 82274 | 1,250 | 1,209 | $16K | |
| 80305 | 3,352 | 1,864 | $15K | |
| 80179 | 1,093 | 953 | $15K | |
| 86038 | 1,406 | 1,332 | $15K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 3,875 | 3,007 | $15K |
| 72040 | 163 | 150 | $15K | |
| 93312 | 30 | 29 | $14K | |
| 80197 | 1,376 | 1,002 | $14K | |
| 87522 | Neg quan hep c or qual rna | 355 | 345 | $14K |
| J3411 | Injection, thiamine hcl, 100 mg | 1,638 | 1,124 | $14K |
| J1790 | Injection, droperidol, up to 5 mg | 1,598 | 1,345 | $13K |
| 84481 | 903 | 855 | $13K | |
| 87653 | 297 | 289 | $13K | |
| 29125 | 127 | 113 | $13K | |
| 86762 | 873 | 816 | $12K | |
| 84156 | 3,907 | 3,447 | $12K | |
| 72170 | 114 | 109 | $11K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 1,340 | 1,123 | $11K |
| 82550 | 2,205 | 1,890 | $11K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 1,108 | 1,015 | $11K |
| 74230 | 73 | 66 | $10K | |
| J1940 | Injection, furosemide, up to 20 mg | 1,856 | 1,434 | $10K |
| 87799 | 312 | 180 | $10K | |
| 84550 | 2,836 | 2,574 | $10K | |
| J9370 | Vincristine sulfate, 1 mg | 108 | 78 | $10K |
| 96368 | 426 | 260 | $10K | |
| 86706 | 1,045 | 977 | $9K | |
| 94760 | 477 | 379 | $9K | |
| 77300 | 14 | 12 | $9K | |
| 82140 | 819 | 679 | $9K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | 54 | 25 | $9K |
| 73120 | 99 | 85 | $8K | |
| 71101 | 69 | 66 | $8K | |
| 92611 | 59 | 52 | $8K | |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 1,662 | 986 | $8K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 3,944 | 1,927 | $8K |
| 90834 | Psychotherapy, 45 minutes with patient | 149 | 63 | $8K |
| 86304 | 574 | 473 | $8K | |
| 0042T | 14 | 14 | $8K | |
| 70491 | 12 | 12 | $8K | |
| 84153 | 521 | 492 | $7K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 3,257 | 2,941 | $7K |
| 97602 | 151 | 90 | $7K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 3,022 | 2,823 | $7K |
| 81003 | 3,863 | 3,429 | $7K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 141 | 133 | $6K |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 69 | 63 | $6K |
| 82310 | 1,688 | 1,453 | $6K | |
| 82977 | 895 | 785 | $6K | |
| 84146 | 338 | 319 | $6K | |
| 73600 | 47 | 41 | $6K | |
| 97127 | 59 | 14 | $6K | |
| T1023 | Screening to determine the appropriateness of consideration of an individual for participation in a specified program, project or treatment protocol, per encounter | 367 | 284 | $5K |
| 96450 | 14 | 13 | $5K | |
| 82150 | 945 | 874 | $5K | |
| 89051 | 1,228 | 1,001 | $5K | |
| 82657 | 187 | 113 | $5K | |
| 87493 | 187 | 169 | $5K | |
| 87497 | 180 | 119 | $5K | |
| 83615 | 1,143 | 884 | $5K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 668 | 518 | $5K |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 1,140 | 874 | $5K |
| C2617 | Stent, non-coronary, temporary, without delivery system | 26 | 25 | $5K |
| 82248 | 992 | 795 | $5K | |
| 80164 | 452 | 384 | $4K | |
| 82565 | 1,036 | 900 | $4K | |
| 87486 | 119 | 111 | $4K | |
| 87581 | 119 | 111 | $4K | |
| 87807 | 297 | 291 | $4K | |
| C1730 | Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) | 15 | 14 | $4K |
| J1453 | Injection, fosaprepitant, 1 mg | 164 | 103 | $4K |
| 78264 | 15 | 12 | $4K | |
| 71250 | 12 | 12 | $4K | |
| 36901 | 113 | 99 | $4K | |
| C1750 | Catheter, hemodialysis/peritoneal, long-term | 34 | 27 | $4K |
| 92610 | 55 | 53 | $4K | |
| 85014 | 2,393 | 2,036 | $4K | |
| D2332 | 14 | 13 | $4K | |
| 84460 | 801 | 733 | $4K | |
| 85018 | 2,028 | 1,729 | $4K | |
| C1760 | Closure device, vascular (implantable/insertable) | 44 | 43 | $4K |
| 86376 | 302 | 286 | $4K | |
| 87427 | 289 | 135 | $3K | |
| 49083 | 16 | 12 | $3K | |
| 82330 | 448 | 238 | $3K | |
| 87147 | 588 | 555 | $3K | |
| J1836 | Injection, metronidazole, 10 mg | 180 | 135 | $3K |
| 87015 | 531 | 445 | $3K | |
| 83001 | 236 | 215 | $3K | |
| 82247 | 552 | 412 | $3K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 591 | 353 | $3K |
| C1788 | Port, indwelling (implantable) | 12 | 12 | $3K |
| A6457 | Tubular dressing with or without elastic, any width, per linear yard | 3,483 | 1,535 | $3K |
| C2623 | Catheter, transluminal angioplasty, drug-coated, non-laser | 46 | 39 | $3K |
| 82533 | 211 | 170 | $3K | |
| 82105 | 207 | 192 | $3K | |
| 84132 | 1,199 | 922 | $3K | |
| 97605 | 62 | 28 | $3K | |
| 83520 | 169 | 163 | $3K | |
| 83655 | 230 | 221 | $3K | |
| 86431 | 508 | 488 | $3K | |
| 76870 | 13 | 13 | $3K | |
| 73070 | 37 | 33 | $3K | |
| J1171 | Injection, hydromorphone, 0.1 mg | 207 | 160 | $2K |
| 86800 | 184 | 174 | $2K | |
| 74019 | 30 | 27 | $2K | |
| 85384 | 410 | 273 | $2K | |
| 83993 | 118 | 111 | $2K | |
| 88173 | 15 | 12 | $2K | |
| 87899 | 157 | 141 | $2K | |
| A6213 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | 271 | 179 | $2K |
| 83525 | 193 | 184 | $2K | |
| 84305 | 100 | 99 | $2K | |
| 82670 | 108 | 99 | $2K | |
| J9045 | Injection, carboplatin, 50 mg | 36 | 24 | $2K |
| T1007 | Alcohol and/or substance abuse services, treatment plan development and/or modification | 13 | 13 | $2K |
| 86200 | 133 | 123 | $2K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 2,512 | 1,954 | $2K |
| 87046 | 169 | 154 | $2K | |
| 87045 | 168 | 154 | $2K | |
| 83002 | 101 | 96 | $2K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 161 | 148 | $2K |
| 86160 | 70 | 65 | $1K | |
| 82950 | 266 | 259 | $1K | |
| A6209 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 352 | 224 | $1K |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 163 | 160 | $1K |
| 87400 | 84 | 60 | $1K | |
| 73552 | 13 | 12 | $1K | |
| J9260 | Injection, methotrexate sodium, 50 mg | 23 | 13 | $1K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 33 | 26 | $1K |
| 86704 | 133 | 127 | $1K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 126 | 105 | $1K |
| 85045 | 216 | 186 | $980.23 | |
| 82785 | 57 | 51 | $932.02 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 15 | 12 | $924.90 |
| 84520 | 260 | 232 | $788.85 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 75 | 43 | $780.24 |
| 80178 | 135 | 110 | $767.14 | |
| 87536 | 12 | 12 | $748.86 | |
| 83013 | 13 | 12 | $714.00 | |
| 84450 | 166 | 156 | $713.43 | |
| H0046 | Mental health services, not otherwise specified | 621 | 398 | $689.12 |
| 84295 | 213 | 164 | $678.07 | |
| J2720 | Injection, protamine sulfate, per 10 mg | 130 | 121 | $625.73 |
| 86308 | 125 | 118 | $596.14 | |
| 84402 | 24 | 24 | $591.76 | |
| L1930 | Ankle foot orthosis, plastic or other material, prefabricated, includes fitting and adjustment | 16 | 14 | $544.52 |
| 85046 | 109 | 95 | $541.38 | |
| 86003 | 29 | 16 | $508.44 | |
| 86682 | 134 | 112 | $489.18 | |
| 82947 | 201 | 171 | $485.21 | |
| 82009 | 141 | 103 | $482.36 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 15 | 12 | $481.03 |
| A6199 | Alginate or other fiber gelling dressing, wound filler, sterile, per 6 inches | 49 | 39 | $456.24 |
| A6234 | Hydrocolloid dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 46 | 31 | $437.52 |
| 84134 | 33 | 26 | $429.38 | |
| 87116 | 43 | 28 | $395.08 | |
| 85347 | 452 | 379 | $379.51 | |
| J0735 | Injection, clonidine hydrochloride, 1 mg | 15 | 13 | $334.95 |
| 87209 | 28 | 14 | $322.74 | |
| L1836 | Knee orthosis, rigid, without joint(s), includes soft interface material, prefabricated, off-the-shelf | 16 | 13 | $322.65 |
| 86255 | 26 | 25 | $322.44 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 37 | 29 | $306.39 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 24 | 24 | $281.16 |
| 82010 | 46 | 38 | $269.61 | |
| 87102 | 26 | 25 | $263.40 | |
| 90686 | 64 | 59 | $261.92 | |
| J7999 | Compounded drug, not otherwise classified | 752 | 611 | $243.68 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 267 | 205 | $215.00 |
| 87338 | 16 | 12 | $205.11 | |
| 87177 | 28 | 14 | $159.75 | |
| 87206 | 45 | 28 | $149.87 | |
| 87420 | 15 | 13 | $139.10 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 302 | 287 | $138.24 |
| 84165 | 17 | 13 | $112.20 | |
| 89060 | 15 | 12 | $100.95 | |
| J0456 | Injection, azithromycin, 500 mg | 15 | 13 | $95.48 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 29 | 24 | $91.55 |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | 17 | 12 | $88.70 |
| 83014 | 13 | 12 | $83.34 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 23 | 12 | $81.84 |
| J7510 | Prednisolone oral, per 5 mg | 13 | 13 | $78.36 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 2,149 | 1,921 | $75.98 |
| 0353U | 2,429 | 2,194 | $70.18 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 154 | 117 | $70.02 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 13 | 13 | $60.48 |
| 82945 | 12 | 12 | $47.16 | |
| 84157 | 12 | 12 | $44.02 | |
| 84155 | 18 | 14 | $42.06 | |
| 87207 | 14 | 13 | $41.33 | |
| A9270 | Non-covered item or service | 46,511 | 14,538 | $8.01 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 37 | 29 | $3.28 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 12,406 | 9,096 | $0.28 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 139 | 135 | $0.00 |
| 86364 | 718 | 690 | $0.00 | |
| 0352U | 1,763 | 1,631 | $0.00 | |
| 86258 | 82 | 80 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 214 | 213 | $0.00 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 88 | 64 | $0.00 |
| 0099U | 12 | 12 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 167 | 138 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 73 | 61 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 141 | 119 | $0.00 |
| 0031A | 84 | 69 | $0.00 | |
| 0011A | 33 | 19 | $0.00 | |
| 97802 | 38 | 36 | $0.00 | |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 38 | 32 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 520 | 449 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 372 | 343 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 81 | 79 | $0.00 |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | 49 | 48 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 470 | 412 | $0.00 |
| 86231 | 97 | 95 | $0.00 | |
| 80348 | 80 | 69 | $0.00 | |
| 90662 | 87 | 86 | $0.00 |